首页 > 最新文献

Arthritis Care & Research最新文献

英文 中文
Hydroxychloroquine and Pre-eclampsia in a Diverse Cohort of Women With Systemic Lupus Erythematosus 羟氯喹与患有系统性红斑狼疮的不同女性群体中的先兆子痫
IF 3.7 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-26 DOI: 10.1002/acr.25386
Julia F. Simard, Emily F. Liu, Amadeia Rector, Miranda Cantu, Eliza Chakravarty, Maurice Druzin, Daniel Z. Kuo, Gary M. Shaw, Michael Weisman, Monique Hedderson

Objective

Patients with systemic lupus erythematosus (SLE) are at risk for pregnancy complications such as pre-eclampsia and eclampsia. These clinically important complications are associated with maternal morbidity, mortality, and postpartum cardiovascular disease. Some studies suggest that hydroxychloroquine (HCQ) may reduce pre-eclampsia risk in lupus pregnancy. Using a cohort of pregnant patients with prevalent SLE at Kaiser Permanente Northern California (KPNC), we investigated whether HCQ treatment in early pregnancy reduced the risk of pre-eclampsia or eclampsia.

Methods

Among pregnant patients with SLE from 2011 to 2020, we assessed HCQ treatment from three months before pregnancy through the first trimester. HCQ exposure was defined multiple ways to account for adherence and duration of treatment. Propensity scores accounted for multiple confounders and modified Poisson models estimated risk ratios (RRs) and 95% confidence intervals of the association between HCQ treatment and pre-eclampsia or eclampsia. Effect modification by pregestational hypertension, history of nephritis, and antiphospholipid antibody (aPL) status was investigated through stratified analysis.

Results

There were 399 pregnancies among 324 patients with SLE at KPNC between 2011 and 2020. Considering multiple exposure definitions, we consistently found a null association between HCQ and pre-eclampsia or eclampsia. The RRs were consistently lower among nullipara patients, and RRs were consistently protective but not statistically significant among the high-risk subgroup of patients with a history of nephritis, aPL positivity, or pregestational hypertension (for both nullipara and multipara patients).

Conclusion

Although this study found no reduced risk of HCQ on pre-eclampsia or eclampsia, residual confounding may be attenuating the effect despite an integrated health care delivery system setting with detailed clinical data.

目的:系统性红斑狼疮(SLE)患者有妊娠并发症(如子痫前期和子痫)的风险。这些临床上重要的并发症与产妇的发病率、死亡率和产后心血管疾病有关。一些研究表明,羟氯喹(HCQ)可降低狼疮妊娠先兆子痫的风险。我们利用北加州凯撒医疗中心(KPNC)的一组系统性红斑狼疮患者的妊娠资料,研究了在妊娠早期使用羟氯喹是否会降低先兆子痫/子痫的风险:在 2011-2020 年间的系统性红斑狼疮孕妇中,我们评估了从孕前三个月到妊娠头三个月使用 HCQ 的情况。HCQ暴露有多种定义方式,以考虑依从性和使用持续时间。倾向评分考虑了多种混杂因素,修正泊松模型估算了HCQ与子痫前期/子痫之间的风险比(RR)和95%置信区间。通过分层分析研究了妊娠高血压、肾炎病史和抗磷脂抗体状态对影响的影响:2011年至2020年期间,324名系统性红斑狼疮患者在KPNC妊娠399例。考虑到多种暴露定义,我们一致发现 HCQ 与先兆子痫/子痫之间呈负相关。在无先兆子痫妊娠中,RRs一直较低,而在有肾炎病史、aPL阳性或妊娠前高血压的高风险亚组(包括无先兆子痫和多胎妊娠)中,RRs一直具有保护作用,但无统计学意义:讨论:尽管本研究发现 HCQ 并未降低子痫前期/子痫的风险,但在综合医疗保健服务系统中,尽管有详细的临床数据,但残留的混杂因素可能会削弱其效果。
{"title":"Hydroxychloroquine and Pre-eclampsia in a Diverse Cohort of Women With Systemic Lupus Erythematosus","authors":"Julia F. Simard,&nbsp;Emily F. Liu,&nbsp;Amadeia Rector,&nbsp;Miranda Cantu,&nbsp;Eliza Chakravarty,&nbsp;Maurice Druzin,&nbsp;Daniel Z. Kuo,&nbsp;Gary M. Shaw,&nbsp;Michael Weisman,&nbsp;Monique Hedderson","doi":"10.1002/acr.25386","DOIUrl":"10.1002/acr.25386","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Patients with systemic lupus erythematosus (SLE) are at risk for pregnancy complications such as pre-eclampsia and eclampsia. These clinically important complications are associated with maternal morbidity, mortality, and postpartum cardiovascular disease. Some studies suggest that hydroxychloroquine (HCQ) may reduce pre-eclampsia risk in lupus pregnancy. Using a cohort of pregnant patients with prevalent SLE at Kaiser Permanente Northern California (KPNC), we investigated whether HCQ treatment in early pregnancy reduced the risk of pre-eclampsia or eclampsia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Among pregnant patients with SLE from 2011 to 2020, we assessed HCQ treatment from three months before pregnancy through the first trimester. HCQ exposure was defined multiple ways to account for adherence and duration of treatment. Propensity scores accounted for multiple confounders and modified Poisson models estimated risk ratios (RRs) and 95% confidence intervals of the association between HCQ treatment and pre-eclampsia or eclampsia. Effect modification by pregestational hypertension, history of nephritis, and antiphospholipid antibody (aPL) status was investigated through stratified analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 399 pregnancies among 324 patients with SLE at KPNC between 2011 and 2020. Considering multiple exposure definitions, we consistently found a null association between HCQ and pre-eclampsia or eclampsia. The RRs were consistently lower among nullipara patients, and RRs were consistently protective but not statistically significant among the high-risk subgroup of patients with a history of nephritis, aPL positivity, or pregestational hypertension (for both nullipara and multipara patients).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although this study found no reduced risk of HCQ on pre-eclampsia or eclampsia, residual confounding may be attenuating the effect despite an integrated health care delivery system setting with detailed clinical data.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.25386","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disparities in Total Knee and Total Hip Arthroplasty Rates in the Population of Alaska, 2015 to 2018 2015-2018 年阿拉斯加州人口全膝关节和全髋关节置换术率的差异。
IF 3.7 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-26 DOI: 10.1002/acr.25394
Elizabeth D. Ferucci, Peter Holck

Objective

Racial and ethnic disparities in total joint replacements have been documented. Our objective was to determine the rates of total joint replacements for Alaska Native/American Indian (AN/AI) individuals compared with non-AN/AI individuals in Alaska and investigate the differences in characteristics and outcomes by race.

Methods

We used hospital discharge data from the Alaska Health Facilities Data Reporting Program from 2015 to 2018. We identified people with an inpatient primary or revision total knee arthroplasty (TKA) or total hip arthroplasty (THA). We determined the population proportion of each procedure, age-adjusted rates by race, age-specific rates, and multivariable adjusted rate ratios for TKA or THA. We compared the characteristics of people undergoing primary TKA and THA by race.

Results

In 2,195,806 person-years, there were 8,131 arthroplasty procedures (4,594 primary TKAs, 2,791 primary THAs, 378 revision TKAs, and 368 revision THAs). Primary TKAs and THAs were less likely in people of AN/AI or “Other” race compared with people of White race, with some heterogeneity in the “Other” race category. In multivariable models, the adjusted rate ratio for AN/AI compared with White race for TKA was 0.70 (95% confidence interval [CI] 0.60–0.82) and for THA was 0.69 (95% CI 0.55–0.85). AN/AI individuals undergoing TKA and THA were more likely to reside in rural locations, be younger than 65 years, have longer hospital stay, and discharge to home.

Conclusion

This study confirmed the existence of racial disparities in TKA and THA in Alaska. There may be many underlying causes, and future research should focus on improving access to care.

目的:全关节置换术中的种族和民族差异已被记录在案。我们的目标是确定阿拉斯加原住民/美洲印第安人(AN/AI)与非阿拉斯加原住民/美洲印第安人相比的全关节置换率,并调查不同种族在特征和结果方面的差异:我们使用了 2015-2018 年阿拉斯加卫生设施数据报告计划的出院数据。我们确定了接受住院初级或翻修全膝关节置换术(TKA)或全髋关节置换术(THA)的患者。我们确定了每种手术的人口比例、按种族划分的年龄调整率、年龄特定率以及 TKA 或 THA 的多变量调整率比。我们按种族比较了接受初级 TKA 和 THA 手术者的特征:在 219.5806 万人年中,共进行了 8131 例关节成形术(4594 例初次 TKA、2791 例初次 THA、378 例翻修 TKA、368 例翻修 THA)。与白种人相比,AN/AI 或其他种族的人接受初次 TKA 和 THA 的可能性较低,其他种族类别中存在一些异质性。在多变量模型中,与白种人相比,AN/AI 的 TKA 调整率比为 0.70(95% 置信区间 (CI) 0.60-0.82),THA 调整率比为 0.69(95% CI 0.55-0.85)。接受TKA和THA手术的AN/AI患者更有可能居住在农村地区、年龄小于65岁、住院时间更长以及出院回家:本研究证实,阿拉斯加州的 TKA 和 THA 存在种族差异。可能有许多潜在的原因,未来的研究应侧重于改善医疗服务的可及性。
{"title":"Disparities in Total Knee and Total Hip Arthroplasty Rates in the Population of Alaska, 2015 to 2018","authors":"Elizabeth D. Ferucci,&nbsp;Peter Holck","doi":"10.1002/acr.25394","DOIUrl":"10.1002/acr.25394","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Racial and ethnic disparities in total joint replacements have been documented. Our objective was to determine the rates of total joint replacements for Alaska Native/American Indian (AN/AI) individuals compared with non-AN/AI individuals in Alaska and investigate the differences in characteristics and outcomes by race.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used hospital discharge data from the Alaska Health Facilities Data Reporting Program from 2015 to 2018. We identified people with an inpatient primary or revision total knee arthroplasty (TKA) or total hip arthroplasty (THA). We determined the population proportion of each procedure, age-adjusted rates by race, age-specific rates, and multivariable adjusted rate ratios for TKA or THA. We compared the characteristics of people undergoing primary TKA and THA by race.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In 2,195,806 person-years, there were 8,131 arthroplasty procedures (4,594 primary TKAs, 2,791 primary THAs, 378 revision TKAs, and 368 revision THAs). Primary TKAs and THAs were less likely in people of AN/AI or “Other” race compared with people of White race, with some heterogeneity in the “Other” race category. In multivariable models, the adjusted rate ratio for AN/AI compared with White race for TKA was 0.70 (95% confidence interval [CI] 0.60–0.82) and for THA was 0.69 (95% CI 0.55–0.85). AN/AI individuals undergoing TKA and THA were more likely to reside in rural locations, be younger than 65 years, have longer hospital stay, and discharge to home.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study confirmed the existence of racial disparities in TKA and THA in Alaska. There may be many underlying causes, and future research should focus on improving access to care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minimal Detectable Changes of the Health Assessment Questionnaire–Disability Index, Patient-Reported Outcomes Measurement Information System-29 Profile Version 2.0 Domains, and Patient Health Questionnaire-8 in People With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Cross-Sectional Study 系统性硬化症患者 HAQ-DI、PROMIS-29v2.0 和 PHQ-8 的最小可检测变化:SPIN 队列横断面研究》。
IF 3.7 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-26 DOI: 10.1002/acr.25397
Afra Alkan, Marie-Eve Carrier, Richard S. Henry, Linda Kwakkenbos, Susan J. Bartlett, Amy Gietzen, Karen Gottesman, Geneviève Guillot, Amanda Lawrie-Jones, Marie Hudson, Laura K. Hummers, Vanessa L. Malcarne, Maureen D. Mayes, Luc Mouthon, Michelle Richard, Robyn K. Wojeck, Maureen Worron-Sauvé, Andrea Benedetti, Brett D. Thombs, the Scleroderma Patient-Centered Intervention Network Investigators

Objective

Systemic sclerosis (SSc) is a rare, chronic autoimmune disorder associated with disability, diminished physical function, fatigue, pain, and mental health concerns. We assessed minimal detectable changes (MDCs) of the Health Assessment Questionnaire–Disability Index (HAQ-DI), Patient-Reported Outcomes Measurement Information System-29 Profile version 2.0 (PROMIS-29v2.0) domains, and Patient Health Questionnaire (PHQ)-8 in people with SSc.

Methods

Scleroderma Patient-Centered Intervention Network Cohort participants completed the HAQ-DI, PROMIS-29v2.0 domains, and PHQ-8 at baseline assessments from April 2014 until August 2023. We estimated MDC95 (smallest change that can be detected with 95% certainty) and MDC90 (smallest change that can be detected with 90% certainty) with 95% confidence intervals (CIs) generated via the percentile bootstrapping method resampling 1,000 times. We compared MDC estimates by age, sex, and SSc subtype.

Results

A total of 2,571 participants were included. Most were female (n = 2,241; 87%), and 38% (n = 976) had diffuse SSc. Mean (±SD) age was 54.9 (±12.7) years and duration since onset of first non-Raynaud phenomenon symptom was 10.8 (±8.7) years. MDC95 estimate was 0.41 points (95% CI 0.40–0.42) for the HAQ-DI, between 4.88 points (95% CI 4.72–5.05) and 9.02 points (95% CI 8.80–9.23) for the seven PROMIS-29v2.0 domains, and 5.16 points (95% CI 5.06–5.26) for the PHQ-8. MDC95 estimates were not materially different across subgroups.

Conclusion

MDC95 and MDC90 estimates were precise and similar across age, sex, and SSc subtype groups. HAQ-DI MDC95 and MDC90 were substantially larger than previous estimates of HAQ-DI minimal important difference from several small studies. Minimally important differences of all measures should be evaluated in large studies using anchor-based methods.

目的:系统性硬化症(SSc)是一种罕见的慢性自身免疫性疾病,与残疾、身体功能减退、疲劳、疼痛和心理健康问题有关。我们对 SSc 患者的健康评估问卷-残疾指数(HAQ-DI)、患者报告结果测量信息系统-29 档案 2.0 版(PROMIS-29v2.0)和患者健康问卷-8(PHQ-8)的最小可检测变化(MDC)进行了评估:硬皮病患者中心干预网络队列参与者在2014年4月至2023年8月的基线评估中完成了HAQ-DI、PROMIS-29v2.0域和PHQ-8。我们估算了 MDC95 和 MDC90,并通过百分位数引导法重新取样 1000 次,得出了 95% 的置信区间 (CI)。我们比较了不同年龄、性别和 SSc 亚型的 MDC 估计值:结果:共纳入 2,571 名参与者。大多数为女性(N = 2,241; 87%),38%(N = 976)患有弥漫性 SSc。平均(标清)年龄为 54.9 (12.7) 岁,自首次出现非雷诺现象症状以来的持续时间为 10.8 (8.7) 年。HAQ-DI的MDC95估计值为0.41点(95% CI:0.40至0.42),PROMIS-29v2.0的7个领域为4.88点(95% CI:4.72至5.05)至9.02点(95% CI:8.80至9.23),PHQ-8为5.16点(95% CI:5.06至5.26)。不同亚组的 MDC95 估计值没有实质性差异:结论:不同年龄、性别和 SSc 亚型组的 MDC95 和 MDC90 估计值精确且相似。HAQ-DI的MDC95和MDC90远大于之前几项小型研究对HAQ-DI最小重要差异的估计值。应在大型研究中使用基于锚的方法评估所有测量指标的最小重要差异。
{"title":"Minimal Detectable Changes of the Health Assessment Questionnaire–Disability Index, Patient-Reported Outcomes Measurement Information System-29 Profile Version 2.0 Domains, and Patient Health Questionnaire-8 in People With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Cross-Sectional Study","authors":"Afra Alkan,&nbsp;Marie-Eve Carrier,&nbsp;Richard S. Henry,&nbsp;Linda Kwakkenbos,&nbsp;Susan J. Bartlett,&nbsp;Amy Gietzen,&nbsp;Karen Gottesman,&nbsp;Geneviève Guillot,&nbsp;Amanda Lawrie-Jones,&nbsp;Marie Hudson,&nbsp;Laura K. Hummers,&nbsp;Vanessa L. Malcarne,&nbsp;Maureen D. Mayes,&nbsp;Luc Mouthon,&nbsp;Michelle Richard,&nbsp;Robyn K. Wojeck,&nbsp;Maureen Worron-Sauvé,&nbsp;Andrea Benedetti,&nbsp;Brett D. Thombs,&nbsp;the Scleroderma Patient-Centered Intervention Network Investigators","doi":"10.1002/acr.25397","DOIUrl":"10.1002/acr.25397","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Systemic sclerosis (SSc) is a rare, chronic autoimmune disorder associated with disability, diminished physical function, fatigue, pain, and mental health concerns. We assessed minimal detectable changes (MDCs) of the Health Assessment Questionnaire–Disability Index (HAQ-DI), Patient-Reported Outcomes Measurement Information System-29 Profile version 2.0 (PROMIS-29v2.0) domains, and Patient Health Questionnaire (PHQ)-8 in people with SSc.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Scleroderma Patient-Centered Intervention Network Cohort participants completed the HAQ-DI, PROMIS-29v2.0 domains, and PHQ-8 at baseline assessments from April 2014 until August 2023. We estimated MDC95 (smallest change that can be detected with 95% certainty) and MDC90 (smallest change that can be detected with 90% certainty) with 95% confidence intervals (CIs) generated via the percentile bootstrapping method resampling 1,000 times. We compared MDC estimates by age, sex, and SSc subtype.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 2,571 participants were included. Most were female (n = 2,241; 87%), and 38% (n = 976) had diffuse SSc. Mean (±SD) age was 54.9 (±12.7) years and duration since onset of first non-Raynaud phenomenon symptom was 10.8 (±8.7) years. MDC95 estimate was 0.41 points (95% CI 0.40–0.42) for the HAQ-DI, between 4.88 points (95% CI 4.72–5.05) and 9.02 points (95% CI 8.80–9.23) for the seven PROMIS-29v2.0 domains, and 5.16 points (95% CI 5.06–5.26) for the PHQ-8. MDC95 estimates were not materially different across subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MDC95 and MDC90 estimates were precise and similar across age, sex, and SSc subtype groups. HAQ-DI MDC95 and MDC90 were substantially larger than previous estimates of HAQ-DI minimal important difference from several small studies. Minimally important differences of all measures should be evaluated in large studies using anchor-based methods.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.25397","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How Does Osteoarthritis Education Influence Knowledge, Beliefs, and Behavior in People With Knee and Hip Osteoarthritis? A Systematic Review 骨关节炎教育如何影响膝关节和髋关节骨关节炎患者的知识、信念和行为?系统综述。
IF 3.7 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-25 DOI: 10.1002/acr.25391
Naomi Simick Behera, Vicky Duong, Jillian Eyles, Haoze Cui, Daniel Gould, Christian Barton, Joletta Belton, David Hunter, Samantha Bunzli

Objective

Our goal was to inform the design and implementation of osteoarthritis (OA) education for people with knee and hip OA. This review investigated the impact of OA education on knowledge, beliefs, and behavior and how and why these changes occur.

Methods

Five databases—MEDLINE, Excerpta Medica Database (Embase), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus, Physiotherapy Evidence Database (PEDro)—were searched in August 2023. Eligible studies were quantitative, qualitative, and mixed-methods, involving OA education interventions and assessing knowledge, beliefs, and/or behavioral outcomes. An interpretivist analytic process guided data evaluation, synthesis, and description of meta-themes.

Results

Ninety-eight studies were included (80 quantitative, 12 qualitative, 6 mixed-methods). OA education was heterogeneous in content and delivery. Outcome measures varied, with poor distinction among knowledge, beliefs, and behavior constructs. Trends toward short-term knowledge improvement were observed, but there were no clear trends in beliefs or behavior change. Intrinsic factors (eg, pre-existing beliefs) and extrinsic factors (eg, socioeconomic factors) appeared to influence change. Three meta-themes described how and why changes may occur: (i) engagement: how individuals relate with education content and delivery; (ii) embodiment: the role of experiential factors in learning, and (iii) empowerment: the level of agency education generates.

Conclusion

Beyond the provision of information and instruction, OA education is a complex, relational process influenced by multidimensional factors. This review identifies potentially important strategies at individual, interpersonal, and community levels to support the design and delivery of engaging education that promotes holistic, embodied learning and facilitates meaningful, empowering change.

目的:为了给针对膝关节和髋关节 OA 患者的骨关节炎(OA)教育的设计和实施提供信息,本综述调查了:i)OA 教育对知识、信念和行为的影响;ii)这些变化是如何发生的以及发生的原因:于 2023 年 8 月检索了五个数据库:MEDLINE、Excerpta Medica Database (Embase)、Cumulative Index to Nursing and Allied Health Literature (CINAHL)、Scopus、Physiotherapy Evidence Database (PEDro)。符合条件的研究包括定量、定性和混合方法,涉及 OA 教育干预,评估知识、信念和/或行为结果。结果:共纳入98项研究:结果:共纳入 98 项研究(80 项定量研究、12 项定性研究和 6 项混合方法研究)。OA 教育的内容和提供方式各不相同。结果衡量标准各不相同,知识、信念和行为建构之间区别不大。观察到短期知识提高的趋势,但在信念或行为改变方面没有明显的趋势。内在因素(如先前存在的信念)和外在因素(如社会经济因素)似乎影响着变化。三个元主题描述了变化发生的方式和原因:i) 参与--个人如何与教育内容和教育方式建立联系;ii) 体现--体验因素在学习中的作用;iii) 赋权--教育产生的代理程度:结论:除了提供信息和指导之外,OA 教育还是一个复杂的、受多维因素影响的关系过程。本综述确定了个人、人际和社区层面的潜在重要策略,以支持设计和提供有吸引力的教育,促进全面的、体现性的学习,并推动有意义的、增强能力的变革。
{"title":"How Does Osteoarthritis Education Influence Knowledge, Beliefs, and Behavior in People With Knee and Hip Osteoarthritis? A Systematic Review","authors":"Naomi Simick Behera,&nbsp;Vicky Duong,&nbsp;Jillian Eyles,&nbsp;Haoze Cui,&nbsp;Daniel Gould,&nbsp;Christian Barton,&nbsp;Joletta Belton,&nbsp;David Hunter,&nbsp;Samantha Bunzli","doi":"10.1002/acr.25391","DOIUrl":"10.1002/acr.25391","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Our goal was to inform the design and implementation of osteoarthritis (OA) education for people with knee and hip OA. This review investigated the impact of OA education on knowledge, beliefs, and behavior and how and why these changes occur.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Five databases—MEDLINE, Excerpta Medica Database (Embase), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus, Physiotherapy Evidence Database (PEDro)—were searched in August 2023. Eligible studies were quantitative, qualitative, and mixed-methods, involving OA education interventions and assessing knowledge, beliefs, and/or behavioral outcomes. An interpretivist analytic process guided data evaluation, synthesis, and description of meta-themes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ninety-eight studies were included (80 quantitative, 12 qualitative, 6 mixed-methods). OA education was heterogeneous in content and delivery. Outcome measures varied, with poor distinction among knowledge, beliefs, and behavior constructs. Trends toward short-term knowledge improvement were observed, but there were no clear trends in beliefs or behavior change. Intrinsic factors (eg, pre-existing beliefs) and extrinsic factors (eg, socioeconomic factors) appeared to influence change. Three meta-themes described how and why changes may occur: (i) engagement: how individuals relate with education content and delivery; (ii) embodiment: the role of experiential factors in learning, and (iii) empowerment: the level of agency education generates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Beyond the provision of information and instruction, OA education is a complex, relational process influenced by multidimensional factors. This review identifies potentially important strategies at individual, interpersonal, and community levels to support the design and delivery of engaging education that promotes holistic, embodied learning and facilitates meaningful, empowering change.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.25391","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does Adding Single-Nucleotide Polymorphisms to Risk Algorithms Improve Cardiovascular Disease Risk Prediction in Rheumatoid Arthritis? An Internal and External Validation of a Clinical Risk Score 在风险算法中加入单核苷酸多态性是否能改善类风湿性关节炎的心血管疾病风险预测?临床风险评分的内外部验证。
IF 3.7 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-24 DOI: 10.1002/acr.25382
Rabia Agca, Calin D. Popa, Martijn W. Heymans, Bart Crusius, Alexandre E. Voskuyl, Michael T. Nurmohamed

Objective

Current risk algorithms do not accurately predict cardiovascular disease (CVD) risk in rheumatoid arthritis (RA). An area of interest is that of single-nucleotide polymorphisms (SNPs), of which several have been associated with CVD in the general population. We investigated whether these SNPs are associated with CVD in RA and whether SNPs could improve CVD risk prediction in RA.

Methods

Sixty SNPs were genotyped in 353 patients with RA. Logistic and Cox regression analyses were performed to identify SNPs that were associated with CVD (n = 99). A prediction model with clinical variables was made. SNPs were added to investigate the additional predictive value. Both models were internally validated. External validation was done in a separate cohort (n = 297).

Results

rs3184504, rs4773144, rs12190287, and rs445925 were significantly associated with new CVD. The clinical prediction model consisted of age, sex, body mass index, systolic blood pressure, high-density lipoprotein cholesterol (HDLc), and creatinine, with an area under the curve (AUC) of 0.74 (P = 0.03). Internal validation resulted in an AUC of 0.76 (P < 0.01). A new model was made including SNPs and resulted in a model with rs17011666 and rs801426, age, total cholesterol, and HDLc, which performed slightly better with an AUC of 0.77 (P < 0.01). External validation resulted in a good fit for the clinical model, but a poor fit for the SNP model.

Conclusion

Several SNPs were associated with CVD in RA. Risk prediction slightly improved after adding SNPs to the models, but the clinical relevance is debatable. However, larger studies are needed to determine more accurately the additional value of these SNPs to CVD risk prediction algorithms.

目的:目前的风险算法不能准确预测类风湿性关节炎(RA)患者的心血管疾病(CVD)风险。单核苷酸多态性(SNPs)是一个值得关注的领域,其中有几个单核苷酸多态性与普通人群中的心血管疾病相关。我们研究了这些 SNPs 是否与 RA 患者的心血管疾病相关,以及 SNPs 是否能改善 RA 患者的心血管疾病风险预测。方法:对 353 名 RA 患者的 60 个 SNPs 进行了基因分型,并进行了 Logistic 和 Cox 回归分析,以确定与心血管疾病相关的 SNPs(n=99)。建立了一个包含临床变量的预测模型。增加了 SNPs 以研究其额外的预测价值。两个模型都经过了内部验证。结果:rs3184504、rs4773144、rs12190287 和 rs445925 与新发心血管疾病显著相关。临床预测模型由年龄、性别、体重指数(BMI)、收缩压(SBP)、高密度脂蛋白胆固醇(HDLc)和肌酐组成,曲线下面积(AUC)为 0.74,P=0.03。内部验证的曲线下面积(AUC)为 0.76(P=0.03):多个SNP与RA患者的心血管疾病相关。将 SNPs 加入模型后,风险预测略有改善,但其临床相关性值得商榷。不过,要更准确地确定这些 SNP 对心血管疾病风险预测算法的额外价值,还需要进行更大规模的研究。
{"title":"Does Adding Single-Nucleotide Polymorphisms to Risk Algorithms Improve Cardiovascular Disease Risk Prediction in Rheumatoid Arthritis? An Internal and External Validation of a Clinical Risk Score","authors":"Rabia Agca,&nbsp;Calin D. Popa,&nbsp;Martijn W. Heymans,&nbsp;Bart Crusius,&nbsp;Alexandre E. Voskuyl,&nbsp;Michael T. Nurmohamed","doi":"10.1002/acr.25382","DOIUrl":"10.1002/acr.25382","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Current risk algorithms do not accurately predict cardiovascular disease (CVD) risk in rheumatoid arthritis (RA). An area of interest is that of single-nucleotide polymorphisms (SNPs), of which several have been associated with CVD in the general population. We investigated whether these SNPs are associated with CVD in RA and whether SNPs could improve CVD risk prediction in RA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Sixty SNPs were genotyped in 353 patients with RA. Logistic and Cox regression analyses were performed to identify SNPs that were associated with CVD (n = 99). A prediction model with clinical variables was made. SNPs were added to investigate the additional predictive value. Both models were internally validated. External validation was done in a separate cohort (n = 297).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>rs3184504, rs4773144, rs12190287, and rs445925 were significantly associated with new CVD. The clinical prediction model consisted of age, sex, body mass index, systolic blood pressure, high-density lipoprotein cholesterol (HDLc), and creatinine, with an area under the curve (AUC) of 0.74 (<i>P</i> = 0.03). Internal validation resulted in an AUC of 0.76 (<i>P</i> &lt; 0.01). A new model was made including SNPs and resulted in a model with rs17011666 and rs801426, age, total cholesterol, and HDLc, which performed slightly better with an AUC of 0.77 (<i>P</i> &lt; 0.01). External validation resulted in a good fit for the clinical model, but a poor fit for the SNP model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Several SNPs were associated with CVD in RA. Risk prediction slightly improved after adding SNPs to the models, but the clinical relevance is debatable. However, larger studies are needed to determine more accurately the additional value of these SNPs to CVD risk prediction algorithms.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.25382","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Explication of Race in Rheumatology Disparities 风湿病学差异中的种族解释。
IF 3.7 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-24 DOI: 10.1002/acr.25388
S. Sam Lim, Paula S. Ramos, Edith M. Williams
{"title":"The Explication of Race in Rheumatology Disparities","authors":"S. Sam Lim,&nbsp;Paula S. Ramos,&nbsp;Edith M. Williams","doi":"10.1002/acr.25388","DOIUrl":"10.1002/acr.25388","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kidney function at diagnosis and during treatment as a predictor of relapse in antineutrophil cytoplasmic antibody–associated vasculitis: comment on the article by Romich et al 诊断时和治疗期间的肾功能是 ANCA 相关性血管炎复发的预测因素。
IF 3.7 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-24 DOI: 10.1002/acr.25389
Tung Lin Lee, Yi Ting Ong, Irene Mok, Hui Zhuan Tan, Jason Choo, Cynthia C Lim
{"title":"Kidney function at diagnosis and during treatment as a predictor of relapse in antineutrophil cytoplasmic antibody–associated vasculitis: comment on the article by Romich et al","authors":"Tung Lin Lee,&nbsp;Yi Ting Ong,&nbsp;Irene Mok,&nbsp;Hui Zhuan Tan,&nbsp;Jason Choo,&nbsp;Cynthia C Lim","doi":"10.1002/acr.25389","DOIUrl":"10.1002/acr.25389","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A 65-Year-Old Man With a Curious Cause of Chronic Arthritis “Hiding in the Pill Box” 一位 65 岁的老人,"藏在药盒里 "的慢性关节炎病因令人费解。
IF 3.7 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-24 DOI: 10.1002/acr.25385
Rafca Challita, Lama Azar
{"title":"A 65-Year-Old Man With a Curious Cause of Chronic Arthritis “Hiding in the Pill Box”","authors":"Rafca Challita,&nbsp;Lama Azar","doi":"10.1002/acr.25385","DOIUrl":"10.1002/acr.25385","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shoulder Symptom Trajectories Over Four Years: Data From a Longitudinal Study on Osteoarthritis 四年来的肩部症状轨迹:一项骨关节炎纵向研究的数据。
IF 3.7 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-24 DOI: 10.1002/acr.25383
Gui Tran, Bright Dube, Sarah R. Kingsbury, Philip G. Conaghan

Objective

Limited data exist on the natural history of shoulder symptoms. We aimed to describe longitudinal patterns of shoulder symptoms and determine risk factors for incidence and persistence.

Methods

Data from Osteoarthritis Initiative participants observed annually for four years were used to describe shoulder symptom (yes/no, side) incidence and prevalence using descriptive analyses. Regression analyses investigated the association among three shoulder symptoms outcomes (persistent, incident, and intermittent) and clinical factors. Latent class growth analysis (LCGA) identified trajectories in those reporting pain at one or more time point.

Results

In total, 4,796 participants (58% women, mean age 61.2 years) were included. Baseline shoulder symptom prevalence was 22%; 32% of these reported bilateral symptoms. In those reporting right symptoms, 260 of 1,886 (14%) had persistent symptoms. Those with persistent symptoms had worse baseline and four-year clinical status (poorer function, mental health, and quality of life). In regression analysis, persistent symptoms were associated with sleep disturbance (adjusted odds ratio [aOR] 1.97, 95% confidence interval [95% CI] 1.49–2.62), work absenteeism (aOR 2.16, 95% CI 1.38–2.62), lower limb weakness (aOR 1.76, 95% CI 1.37–2.27), multiple-site joint symptoms (≥3 joints excluding shoulders) (aOR 4.90, 95% CI 2.79–8.58) and White race (aOR 1.39, 95% CI 1.04–1.88). Lower limb weakness was also associated with incident symptoms; no variables were associated with intermittent symptoms. LCGA identified two trajectories: the trajectory with high probability for symptoms (9% of LCGA analysis cohort) showed similar relationships to clinical variables as in the persistent symptoms group.

Conclusion

In this large, four-year study, persistent shoulder symptoms were common and associated with worse clinical outcomes. At least one risk factor for incident symptoms is modifiable.

目的:有关肩部症状自然史的数据有限。我们旨在描述肩部症状的纵向模式,并确定发病率和持续性的风险因素:方法:我们使用骨关节炎倡议参与者的数据,对其进行了为期 4 年的年度随访,并使用描述性分析描述了肩部症状(是/否、侧面)的发生率和流行率。回归分析研究了三种肩部症状结果(持续性、偶发性和间歇性)与临床因素之间的关联。潜类增长分析(LCGA)确定了在≥1个时间点报告疼痛的患者的轨迹:共纳入 4796 名参与者(58% 为女性,平均年龄 61.2 岁)。基线肩部症状发生率为 22%;其中 32% 报告了双侧症状。在报告右侧症状的人中,260/1886(14%)人有持续性症状。有持续症状者的基线和四年临床状况较差(功能、心理健康和生活质量较差)。在回归分析中,持续症状与以下因素相关:调整后 OR(95% CI):睡眠障碍(1.97(1.49,2.62))、旷工(2.16(1.38,2.62))、下肢无力(1.76(1.37,2.27))、多部位关节症状(≥3 个关节,不包括肩部)4.90(2.79,8.58)和白人(1.39(1.04,1.88)。下肢无力也与偶发症状有关;没有变量与间歇性症状有关。LCGA确定了两种轨迹:症状发生概率高的轨迹(占LCGA分析队列的9%)显示出与持续症状组临床变量相似的关系:在这项为期4年的大型研究中,持续性肩部症状很常见,并且与较差的临床结果相关。至少有一个风险因素是可以改变的。
{"title":"Shoulder Symptom Trajectories Over Four Years: Data From a Longitudinal Study on Osteoarthritis","authors":"Gui Tran,&nbsp;Bright Dube,&nbsp;Sarah R. Kingsbury,&nbsp;Philip G. Conaghan","doi":"10.1002/acr.25383","DOIUrl":"10.1002/acr.25383","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Limited data exist on the natural history of shoulder symptoms. We aimed to describe longitudinal patterns of shoulder symptoms and determine risk factors for incidence and persistence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from Osteoarthritis Initiative participants observed annually for four years were used to describe shoulder symptom (yes/no, side) incidence and prevalence using descriptive analyses. Regression analyses investigated the association among three shoulder symptoms outcomes (persistent, incident, and intermittent) and clinical factors. Latent class growth analysis (LCGA) identified trajectories in those reporting pain at one or more time point.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 4,796 participants (58% women, mean age 61.2 years) were included. Baseline shoulder symptom prevalence was 22%; 32% of these reported bilateral symptoms. In those reporting right symptoms, 260 of 1,886 (14%) had persistent symptoms. Those with persistent symptoms had worse baseline and four-year clinical status (poorer function, mental health, and quality of life). In regression analysis, persistent symptoms were associated with sleep disturbance (adjusted odds ratio [aOR] 1.97, 95% confidence interval [95% CI] 1.49–2.62), work absenteeism (aOR 2.16, 95% CI 1.38–2.62), lower limb weakness (aOR 1.76, 95% CI 1.37–2.27), multiple-site joint symptoms (≥3 joints excluding shoulders) (aOR 4.90, 95% CI 2.79–8.58) and White race (aOR 1.39, 95% CI 1.04–1.88). Lower limb weakness was also associated with incident symptoms; no variables were associated with intermittent symptoms. LCGA identified two trajectories: the trajectory with high probability for symptoms (9% of LCGA analysis cohort) showed similar relationships to clinical variables as in the persistent symptoms group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this large, four-year study, persistent shoulder symptoms were common and associated with worse clinical outcomes. At least one risk factor for incident symptoms is modifiable.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.25383","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perspective of Dutch Patients with Gout on Continuation or Discontinuation of Urate-Lowering Therapy During Remission: A Mixed-Methods Study 荷兰痛风患者对缓解期继续或停止降尿酸治疗的看法:一项混合方法研究。
IF 3.7 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-06-24 DOI: 10.1002/acr.25392
Iris Rose Peeters, Frouwke Veenstra, Sophie A. C. Wanten, Johanna E. Vriezekolk, Cornelia H. van den Ende, Alfons A. den Broeder, Noortje van Herwaarden, Lise M. Verhoef, Marcel Flendrie

Objective

Long-term gout management is based on reducing serum urate by using urate-lowering therapy (ULT). A lifelong treat-to-target approach is advocated, although a ULT (taper to) stop attempt can be considered (treat-to-avoid symptoms approach) during remission. Exploring the beliefs of patients with gout on long-term ULT strategies during remission is important for optimizing gout management. We aimed to identify factors that influence the decision for continuation or discontinuation of ULT and to determine their relative importance according to patients with gout in remission.

Methods

A mixed-methods design was used. First, semistructured interviews (substudy 1) were conducted to identify barriers and facilitators for the (dis)continuation of ULT using inductive thematic analysis. Afterwards, these barriers/facilitators were summarized into neutrally phrased items and used in a maximum difference scaling study (substudy 2) to determine their relative importance using the rescaled probability score.

Results

Substudies 1 and 2 included 18 and 156 patients, respectively. Substudy 1 yielded 22 items within 10 overarching themes. Substudy 2 revealed that the perceived risk of joint damage and gout flares and that ULT use gives some assurance were the most important items. The costs, ease of receiving ULT, and its practical use were the least important items.

Conclusion

These results can aid shared decision-making and provide input for what is important to discuss with patients with gout in remission when they consider ULT discontinuation. The emphasis should be on the risk of having gout flares and joint damage, not so much on facilitating how easily medication is received.

背景:痛风的长期治疗以通过降尿酸盐疗法(ULT)降低血清尿酸盐为基础1、2。尽管在缓解期可以考虑尝试停止超低尿酸治疗(减量至)(从治疗到避免症状的方法),但仍提倡终生从治疗到目标的方法。探讨痛风患者对缓解期长期超量治疗策略的看法对于优化痛风治疗非常重要:确定影响继续或停止超量治疗决定的因素,并根据处于缓解期的痛风患者确定这些因素的相对重要性:方法:采用混合方法设计。首先,进行了半结构式访谈(子研究 1),利用归纳式主题分析确定了(不)继续使用 ULT 的障碍和促进因素。然后,将这些障碍/促进因素归纳为中性措辞的项目,并在最大差异标度研究(MaxDiff,子研究 2)中使用重标概率分(RPS)确定其相对重要性:子研究 1 和子研究 2 分别包括 18 名和 156 名患者。子研究 1 在 10 个总体主题中产生了 22 个项目。子研究 2 显示,认为关节损伤和痛风复发的风险以及使用超短波治疗能在一定程度上保证超短波治疗的使用是最重要的项目。结论:这些结果有助于共同决策,并为处于缓解期的痛风患者在考虑停用超短波治疗时需要讨论的重要事项提供了参考。重点应放在痛风复发和关节损伤的风险上,而不是如何方便地接受药物治疗上。
{"title":"Perspective of Dutch Patients with Gout on Continuation or Discontinuation of Urate-Lowering Therapy During Remission: A Mixed-Methods Study","authors":"Iris Rose Peeters,&nbsp;Frouwke Veenstra,&nbsp;Sophie A. C. Wanten,&nbsp;Johanna E. Vriezekolk,&nbsp;Cornelia H. van den Ende,&nbsp;Alfons A. den Broeder,&nbsp;Noortje van Herwaarden,&nbsp;Lise M. Verhoef,&nbsp;Marcel Flendrie","doi":"10.1002/acr.25392","DOIUrl":"10.1002/acr.25392","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Long-term gout management is based on reducing serum urate by using urate-lowering therapy (ULT). A lifelong treat-to-target approach is advocated, although a ULT (taper to) stop attempt can be considered (treat-to-avoid symptoms approach) during remission. Exploring the beliefs of patients with gout on long-term ULT strategies during remission is important for optimizing gout management. We aimed to identify factors that influence the decision for continuation or discontinuation of ULT and to determine their relative importance according to patients with gout in remission.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A mixed-methods design was used. First, semistructured interviews (substudy 1) were conducted to identify barriers and facilitators for the (dis)continuation of ULT using inductive thematic analysis. Afterwards, these barriers/facilitators were summarized into neutrally phrased items and used in a maximum difference scaling study (substudy 2) to determine their relative importance using the rescaled probability score.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Substudies 1 and 2 included 18 and 156 patients, respectively. Substudy 1 yielded 22 items within 10 overarching themes. Substudy 2 revealed that the perceived risk of joint damage and gout flares and that ULT use gives some assurance were the most important items. The costs, ease of receiving ULT, and its practical use were the least important items.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These results can aid shared decision-making and provide input for what is important to discuss with patients with gout in remission when they consider ULT discontinuation. The emphasis should be on the risk of having gout flares and joint damage, not so much on facilitating how easily medication is received.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.25392","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Arthritis Care & Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1